1. Home
  2. QNTM vs LOAN Comparison

QNTM vs LOAN Comparison

Compare QNTM & LOAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QNTM
  • LOAN
  • Stock Information
  • Founded
  • QNTM 1998
  • LOAN 1989
  • Country
  • QNTM Canada
  • LOAN United States
  • Employees
  • QNTM N/A
  • LOAN N/A
  • Industry
  • QNTM
  • LOAN Real Estate Investment Trusts
  • Sector
  • QNTM
  • LOAN Real Estate
  • Exchange
  • QNTM NYSE
  • LOAN Nasdaq
  • Market Cap
  • QNTM 69.3M
  • LOAN 58.1M
  • IPO Year
  • QNTM N/A
  • LOAN 1999
  • Fundamental
  • Price
  • QNTM $25.15
  • LOAN $5.43
  • Analyst Decision
  • QNTM
  • LOAN
  • Analyst Count
  • QNTM 0
  • LOAN 0
  • Target Price
  • QNTM N/A
  • LOAN N/A
  • AVG Volume (30 Days)
  • QNTM 188.7K
  • LOAN 26.7K
  • Earning Date
  • QNTM 08-13-2025
  • LOAN 07-22-2025
  • Dividend Yield
  • QNTM N/A
  • LOAN 8.47%
  • EPS Growth
  • QNTM N/A
  • LOAN N/A
  • EPS
  • QNTM N/A
  • LOAN 0.48
  • Revenue
  • QNTM N/A
  • LOAN $7,300,469.00
  • Revenue This Year
  • QNTM N/A
  • LOAN N/A
  • Revenue Next Year
  • QNTM N/A
  • LOAN $4.41
  • P/E Ratio
  • QNTM N/A
  • LOAN $11.31
  • Revenue Growth
  • QNTM N/A
  • LOAN N/A
  • 52 Week Low
  • QNTM $2.70
  • LOAN $4.74
  • 52 Week High
  • QNTM $38.25
  • LOAN $6.05
  • Technical
  • Relative Strength Index (RSI)
  • QNTM 61.07
  • LOAN 50.61
  • Support Level
  • QNTM $21.63
  • LOAN $5.31
  • Resistance Level
  • QNTM $24.61
  • LOAN $5.69
  • Average True Range (ATR)
  • QNTM 2.37
  • LOAN 0.20
  • MACD
  • QNTM 0.27
  • LOAN -0.02
  • Stochastic Oscillator
  • QNTM 91.60
  • LOAN 36.73

About QNTM QUANTUM BIOPHARMA LTD

Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.

About LOAN Manhattan Bridge Capital Inc

Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.

Share on Social Networks: